Rocket Pharma's Gene Therapy for Rare Pediatric Disease Faces Delay in FDA Approval
Last Friday, Rocket Pharma announced that the US health regulatory agency had not approved its investigational gene therapy for a rare and severe pediatric disease that significantly impacts the patients' immune system function. This news led to a significant over 12% drop in the company's stock price in early trading.
According to reports, the US Food and Drug Administration (FDA) responded with a detailed letter, requesting Rocket to provide limited additional information on certain processes for its gene therapy candidate named Kresladi, in order to complete a comprehensive review. Rocket is seeking the FDA's first approval for this therapy to treat severe Leukocyte Adhesion Deficiency-I (LAD-I) patients, with an estimated 800 to 1,000 patients affected in the US and Europe.
In these patients, a mutation in the protein encoded by the ITGB2 gene prevents white blood cells from properly adhering to the vessel walls at sites of infection, potentially leading to severe immune dysfunction and recurrent infections. Rocket stated that it has met with the FDA and discussed the required information to expedite the approval process.
The marketing authorization application is based on early to mid-stage clinical trial data, where all 9 patients treated survived at least 12 months post-treatment. However, in February this year, the FDA extended the review timeline for certain process data related to this gene therapy.
Analyst Tyler Van Buren from TD Cowen commented that this delay appears to be related to internal bandwidth issues at the FDA, rather than any issues with Rocket itself. He also noted that while Kresladi represents a relatively smaller market opportunity for Rocket, a successful approval would strongly validate the company's lentiviral platform, which is working to provide other treatment options for more patient populations.
Currently, the only treatment option for this disease is bone marrow transplantation, which is often difficult to obtain and carries significant risks.
2026-10-23
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Approves ₹30.3 Billion Chemical-Park Scheme to Build Three Mega Industrial Hubs
-
EFSA’s Updated Food-Additive Application Guidance Takes Effect
-
FDA Revokes Orange B Authorization and Proposes Removing Citrus Red No. 2
-
“全球展会数据”功能上线公告 Announcement on the Launch of the “Global Exhibition Data” Function
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
U.S. Announces Preliminary Dumping Margins of Up to 70.21% on Chinese Xanthan Gum
-
FDA Dye Tracker Raises Reformulation Pressure Across Food Brands
Recommend Reading
-
Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
Both Costs and Consumption Weak, ABS Continues to Decline
-
Under the Game of Multiple Factors, the PTA Market Enters a Phased Correction
-
Premium Global Chemical Sourcing Requests (24 - 28 Jan, 2026)
-
Business Society’s MTBE Market Outlook on August 17, 2026: Slightly Bearish Consolidation
-
What is Serine? (Amino Acid Function & Sources)
- Hot Searches
- potassium cyanide for sale
- propylene glycol prices
- raw tadalafil powder
- what's the price of kerosene
- na 931 buy online
- sodium thiosulfate pentahydrate sds
- buy 2cb online
- glycol price
- flour treatment agent
- retatrutide peptide supplier
- azithromycin dihydrate api market price 2026
- food grade tannic acid for sale